Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...

Alumis (NASDAQ:ALMS – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) ...

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Alumis Inc. (ALMS – Research Report) and Martin ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

Alumis (ALUM) stock dropped while Acelyrin (SLRN) stock gained in the premarket as the biopharma companies announced an all-stock merger deal. Read more here.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN ...

Alumis (Nasdaq: ALMS) and Acelyrin (Nasdaq: SLRN) have agreed to merge in an all-stock deal, creating a late-stage ...